NCT Number: NCT02421380
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
The purpose of the study is to test a new approach to see if the test results can be reproduced each time the Magnetic resonance imaging (MRI) is done for an individual patient. The study will explore the use of an imaging agent called hyperpolarized [1-13C] pyruvate (HP) with MRI scans. (MRI) is a technique that takes pictures of the body's organs using a magnetic field and radiofrequency waves that cannot be felt. In order to accomplish the goal of the study the patient will have two hyperpolarized MRI scans to assess if scans can be reproduced. The hyperpolarized MRI scans will be compared with the pathological results of the surgery to see if the hyperpolarized MRI provides additional information regarding disease metabolism.
Interested in participating?
Request InfoKey information
Conditions
Age range
21 year–90 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
Memorial Sloan Kettering Bergen (Consent only ), Montvale, New Jersey, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patients with history of histologically-confirmed malignant solid tumor (histology confirmed by MSKCC Department of Pathology.) NOTE: An exception will be made for patients with brain lesions. Patients identified by a radiologist to have a brain lesion with high suspicion for neoplasm given MRI features will be enrolled, prior to histological confirmation.
- Disease measurable or evaluable as defined by RECIST 1.1, a mass of greater than 1cm in the long axis and/or other tumor response criteria from an MSKCC IRB-approved clinical research protocol. NOTE: Study patients do not need to be participating in an MSKCC approved clinical trial prior to study recruitment.
- Negative serum or urine pregnancy test for female patients of childbearing age and potential (as defined by MSKCC Standards & Guidelines), from assays obtained < 2 weeks prior to study enrollment.
- This study will include only patients with sarcoma, prostate, breast, brain, metastatic or pancreatic cancer. In the future other patient groups may be included through amendment of this protocol.
Exclusion criteria
- Inability or refusal to have at least one peripheral intravenous line for intravenous access (as applicable to the day of [1-13C] pyruvate injection)
- Breast-feeding
- Refusal or inability to tolerate the scanning procedure (e.g., due to claustrophobia)
- Hepatic: from assays obtained within 3-4 weeks prior to study enrollment. For each patient, the upper limit of normal (ULN) value for a particular assay will be defined by the normal reference values of the laboratory that performed the assay
- Bilirubin > 1.5 x (ULN)
- AST/ALT >2.5 x ULN
- Albumin < 3 g/dl
- GGT > 2.5 x ULN if Alkaline phosphatase > 2.5 x ULN.
- Renal: Creatinine >1.5 x ULN or creatinine clearance < 60 mL/min, from assays obtained within 3-4 weeks prior to study enrollment
- Acute major illness (e.g., unstable cardiovascular condition, etc.)
- Standard MRI exclusion criteria will also be applied, including pacemakers and metal clips located in the patient.
Treatment and study plan
Primary outcomes
-
validate HP MRI at MSKCC (are the scans able to be reproduced)
Time frame: 1 year
The imaging will include standard T2-weighted, diffusion-weighted (DW), dynamic contrast-enhanced (DCE) and 1H MR spectroscopic imaging, depending on the solid tumor type. This multi-parametric data will be used to delineate the tumor as well as compare to HP MRI.
Study contacts
Contact information is provided by the study sponsor or research team.
Kayvan Keshari, PhD
CONTACT
Vesselin Miloushev, MD
CONTACT
Sponsors and collaborators
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Registry information
Important dates
- Study start
- 2015
- Primary completion
- 2027
- Study completion
- 2027
- First posted
- Apr 20, 2015
- Registry last updated
- Jul 21, 2026
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
NCT03739827
Malignant Solid Tumors, Other Neoplasms Solid Tumors
Bethesda, Maryland, United States
View Trial DetailsPhase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia
NCT06629584
Malignant Solid Tumors
Houston, Texas, United States
View Trial DetailsA Study of TAK-505 in Adults With Solid Tumors
NCT07436728
Malignant Solid Tumors
Orange, California, United States
View Trial DetailsA Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors
NCT07028281
Malignant Solid Tumors
Jinan, Shandong, China
View Trial Details